HIMS Gains Analyst Support After GLP-1 Deal<\/p>\n
Citigroup upgraded Hims & Hers to ‘Neutral’ from ‘Sell’ and raised its price target to $24 from $13.25, implying a 7% upside from the stock\u2019s last close. The bank said the renewed partnership with Novo Nordisk \u201csignificantly de-risks\u201d the company and pointed to Novo\u2019s decision to drop its patent infringement lawsuit, which it said removes a major legal overhang.<\/p>\n
Meanwhile, Needham upgraded the stock to ‘Buy’ from ‘Hold’ with a $30 price target, suggesting a 34% upside from current levels. The research firm said its previous Hold rating had been based on Hims & Hers being boxed out of the weight-loss market, but now believes the Novo Nordisk partnership fundamentally changes the company\u2019s weight-loss business and overall growth algorithm, according to an Investing\u00a0report<\/a>.<\/p>\n Needham added that the deal could unlock stronger demand tied to Novo\u2019s blockbuster GLP-1 drugs, particularly as medications such as Wegovy are often purchased through cash-pay channels that are not fully reflected in the company\u2019s outlook.<\/p>\n Research firm Morningstar took a more cautious stance, maintaining a $23 fair value estimate, which implies about 3% upside from the latest close, while calling the shares \u201cfairly valued\u201d following the sharp rally and noting that uncertainties around the renewed partnership remain.<\/p>\n Short Sellers Feel The Pain<\/p>\n The stock\u2019s surge also triggered massive losses for short sellers. According to a\u00a0post on X<\/a> by Ihor Dusaniwsky, managing director at S3 Partners, traders betting against the stock lost about $546 million in mark-to-market losses in a single day as the rally forced pressure on bearish positions.<\/p>\n Dusaniwsky said Hims & Hers currently has about $1.39 billion in short interest, representing 87.94 million shares, or 42.83% of the stock\u2019s float. However, bearish traders remain up about $757 million so far this year.<\/p>\n Short sellers have now lost roughly $258 million over the past 30 days. \u201cThese daily losses may trigger squeeze-related short covering in this heavily shorted stock,\u201d Dusaniwsky added.<\/p>\n Novo Nordisk Deal Resets Hims GLP-1 Strategy<\/p>\n The rally followed Hims & Hers\u2019 announcement of a\u00a0new deal<\/a> with Novo Nordisk, which will allow the telehealth platform to distribute several FDA-approved GLP-1 treatments. Under the agreement, the company will offer Novo\u2019s Ozempic injections and Wegovy pills and injections through its platform starting later this month as part of a broader strategy to focus on branded, FDA-approved medications.<\/p>\n Additionally, Hims said it will stop advertising compounded GLP-1 drugs, though it plans to continue offering them for a limited set of patients if a provider determines a compounded product is clinically necessary.<\/p>\n Novo Nordisk withdrew its patent infringement lawsuit against the company, removing a dispute that had escalated over the past few months after Hims signaled plans to offer a copycat version of Novo\u2019s weight-loss pill.<\/p>\n FDA Commissioner Welcomes Deal<\/p>\n Marty Makary, commissioner of the U.S. Food and Drug Administration (FDA), welcomed the\u00a0deal on X<\/a>, saying, \u201cGlad to see HIMS will stop advertising unapproved compounded drugs and instead sell FDA-approved products through its new partnership with Novo Nordisk.\u201d<\/p>\n Makary added that the agreement keeps medications affordable while limiting compounded GLP-1 use to rare cases that comply with FDA guidelines.<\/p>\n How Did Stocktwits Users React?<\/p>\n On Stocktwits, retail sentiment was \u2018extremely bullish\u2019 amid \u2018extremely high\u2019 message volume.<\/p>\n One bullish user\u00a0noted<\/a> that \u201cshorts reloaded for another opener attack tomorrow.\u00a0 It’s do or die for them starting tomorrow.\u201d<\/p>\n Another user\u00a0said<\/a>, \u201cThere’s no downside now.. FDA risk, Litigations, can sell NOVO products, purchase of Eucalyptus,\u00a0 a round of rating upgrades no doubt. As there’s no need to short, shorts will start to close positions. \u201c<\/p>\n HIMS stock has declined 32% year-to-date.<\/p>\n For updates and corrections, email newsroom[at]stocktwits[dot]com.<\/p>\n![\"hims](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/03\/hims_ss_png_08adce1a14.webp.png\")
HIMS sentiment and message volume as of March 10 | Source: Stocktwits<\/p>\n
![\"Add](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/02\/1771061752_645_icon-google.2109d02c.png\"){kind=icon}
<\/a><\/p>\n